| 18 April 2012 - Spinnovation Biologics Predicts Biomanufacturing Success |
|
NEWS RELEASE Spinnovation Biologics Predicts Biomanufacturing Success 18 April 2012: Spinnovation Biologics, Nijmegen, The Netherlands: With expertise and know-how in high-end analysis for biologics, Spinnovation Biologics today announces the launch of a breakthrough solution – Spedia-Predict™ – for Bioprocess performance troubleshooting and performance prediction of bioproduction, at the annual Bioprocess International European meeting. Spedia-Predict™ monitors and validates process-critical parameters as a company looks to manage the culture media consistency used in their production environment. Good Manufacturing Practice (GMP) and FDA Quality by Design (QbD) approaches demand close control, but traditional analytical methodology can be costly, time consuming and require sample preparation ahead of measurement. They also lack the ability to characterize chemically complex media. As a result, many companies monitor only a handful of components, failing to get the complete picture and missing information on how it will perform in scale-up. Spedia-Predict™ rapidly profiles most constituents in a medium; it delivers quantitative data and can be applied equally to chemically fully defined or complex media. Spedia-Predict™ allows identification of markers that can correlate with performance of a specific bioprocess, and monitor batch to batch consistency, for example. As a result, it helps to prevent failure and performance variability in large-scale commercial production, by enabling efficient and cost-effective processes. Dr Frederic Girard, CEO, said, "Using Spedia-Predict™ we help our clients to understand and monitor the factors that are most influential to their cell culture performance. This is a huge advantage. Importantly, we provide information early in production planning – effectively establishing a QC standard – which can then be used in routine manufacturing to reduce the risk of process failure, and increase the consistency in production performance. Risk factors are reduced and replaced with consistent, reproducible results." Spinnovation's core expertise in Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectrometry (MS) to study molecules and materials is increasingly being applied in the biopharma production environment. The introduction of Spedia-Predict™ demonstrates the company's continuous efforts to develop and implement new analytical methods to meet most demanding industry requirements. For further information, please visit Spedia-Predict™ webpage. End Spedia-Predict™ is a registered trademark of Spinnovation Analytical BV
(complete Press Release in pdf)
About Spinnovation Analytical BV Spinnovation Biologics is a division of Spinnovation Analytical BV (Nijmegen, The Netherlands, www.spinnovation-analytical.com). Spinnovation is a contract research organization expert in delivering analytical service to the Industry (Pharmaceuticals, Chemicals/Polymers, Food Products). Its expertise and core activity focuses on the use of Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectrometry (MS) to study molecules and materials.
For press information, please contact: Alexandra Jones, Kapler Communications Tel: +44 (0)1480 471059; Fax: +44 (0)1480 471069 This e-mail address is being protected from spambots. You need JavaScript enabled to view it Spinnovation contact: Dr. Frederic Girard, Spinnovation Analytical BV |